Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

Moderna Inc. closed $130.88 short of its 52-week high ($170.47), which the company reached on May 24th.

A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to news from the U.S. Food and ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the ...